Browse by Monitor

BD Surgical Reconstructive and Hemostatic Solutions

(PM P1) 5-hydroxymethylation Signatures in Plasma Circulating Cell-Free DNA as Markers for Appendiceal and Colorectal Peritoneal Metastasis

(PM P2) Association of Muscle Quantity and Frailty on Short-term Outcomes of CRS/HIPEC in Patients with Appendiceal Cancer

(PM P3) Gold Nanorod-Mediated Hyperthermia Can Improve Chemotherapeutic Efficacy in HIPEC

(PM P4) Impact of Cellularity in Peritoneal Metastases on Survival in Patients with Low-Grade Appendiceal Mucinous Neoplasm (LAMN)

(PM P5) Implications of Postoperative Complications on Survival after CRS/HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative

(PM P6) Incomplete Cytoreductive Surgery for Appendiceal and Colorectal Peritoneal Carcinomatosis: Characteristics and Outcomes of an Overlooked Group

(PM P7) Outcomes of Palliative CRS/HIPEC for Patients with Advanced Peritoneal Carcinomatosis from Appendiceal Cancer

(PM P8) Preoperative Lymphocyte-to-Monocyte Ratio Predicts Survival in HIPEC/ CRS for Colorectal and Appendiceal Adenocarcinoma

(PM P9) Site-specific Molecular Comparison Between Primary Gastric (GC) and Gastroesophageal Junction (GEJ) Cancer Emphasizing Peritoneal Metastases (PM)

(HPB P1) Risk of Performing Concurrent Procedures with Hepatic Artery Infusion

(HPB P2) Robotic Major Hepatectomy: An Institutional Eexperience and Clinical Outcomes

(HPB P3) Analysis of Cholyglycine Acid as a Biomarker for the Early Diagnosis of Liver Disease

(HPB P4) Clinical Significance of SMAD4 Mutation Status in Patients with Resected Colorectal Liver Metastases

(PM P10) The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC

BD Surgical Reconstructive and Hemostatic Solutions

(PM P11) Carboplatin Hyperthermic Intraperitoneal Chemotherapy is Safe and Efficacious in Recurrent and Advanced Ovarian Cancer

(PM P12) Impact of Histology on Survival in Colon Cancer with Peritoneal Carcinomatosis: Does it really matter?

(PM P13) Laparoscopic HIPEC for Low-volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma

(PM P14) Lymph Node Metastasis in Mucinous Appendiceal Adenocarcinoma

(PM P15) Prognostic Factors And Outcomes Of Non-Invasive Mucinous Appendiceal Neoplasms With And Without Peritoneal Spread

(PM P16) The Use of Predictive Modeling for Prolonged Hospital Length of Stay in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

(PM P17) A Multi-institutional Analysis of Major Organ Resection in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma

(PM P18) Interim Results of Phase II Trial for Novel Magnetic Resonance Imaging of Peritoneal Mesothelioma

(PM P19) Mitomycin C versus Oxaliplatin During Cytoreductive Surgery and HIPEC for Peritoneal Metastases Secondary to Colorectal Carcinoma: A Retrospective Analysis

(PM P20) National Trends In Cytoreductive Surgery with Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin: An Analysis of the National Cancer Database

(PM P21) Outcomes in Elderly Ovarian Cancer Patients Treated with CytoreductiveSurgery plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

(PM P22) Pelvic Anastomosis without Protective Ileostomy is Safe in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

(PM P23) Rate of Peritoneal Carcinomatosis in Surgically-Resected Stage II and III Colon Cancer

(PM P24) Survival Benefits of Redo Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Recurrent Peritoneal Carcinomatosis

(O P1) Analysis of ERAS Protocol in Patients Undergoing Pancreaticoduodenectomy

(O P2) Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy and Subsequent Fertility: Should We Be Doing More?

(PM P26) Symptomatic Presentation Harbors Worse Prognosis With Low Grade Appendiceal Mucinous Neoplasm

(PM P27) Anesthesia and Pain Management of Pediatric Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors Utilizing a Tunneled Thoracic Epidural; Initiation of a New Pediatric HIPEC Program

(PM P28) Completeness of Cytoreduction, Regardless of Tumor Burden, is Associated with Improved Survival after CRS/HIPEC for LAMN

(PM P29) Development of a Novel Enhanced Recovery After Surgery Protocol (ERAS) For Cytoreductive Surgery & HIPEC

(PM P30) Outcomes of CS-HIPEC Among Patients with Colorectal and Appendiceal Adenocarcinoma Versus Signet-ring Cell Carcinoma

(PM P31) Volume of Intraoperative Crystalloid Administration is Associated with Postoperative Respiratory Failure following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

(PM P32) A Conservative Approach To Enteral Feeding After Cytoreductive Surgery and HIPEC Leads To Improved Outcomes

(PM P33) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin in Pediatric Patients with Peritoneal Mesothelioma: A Single Institution Experience and Long Term Follow Up

(PM P34) Influence of Older Age on the Prognosis after CRS+HIPEC for Peritoneal Carcinomatosis of Appendiceal Origin

(PM P35) Is Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Safe in Septuagenarians?

(PM P36) Should Ascites be a Contraindication to Laparoscopic HIPEC in Gastric Cancer?

(PM P37) The Impact of Postoperative Peritoneal Carcinomatosis Index on Survival of Patients with Peritoneal Surface Malignancy from Appendiceal Origin after CRS/HIPEC

(O P3) Hospital Variation in Perioperative Outcomes of Cytoreductive Surgery for Cancer: Implications for Quality Measurement

(O P5) Percutaneous Cryoablation: A Novel First-Line Therapy for Extra-Abdominal Desmoid Tumors

(O P6) Focused Ultrasound and Concurrent Chemotherapy for Locally Advanced Pancreatic Cancer: A Systematic Review

(O P7) Upper Abdominal Stopflow Perfusion - The Surgical Technique Behind Locally High Drug Concentrations

(AR P2) Cellular Immunoprofile of Peritoneal Environment during HIPEC Procedure

(AR P3) Y-90 PET Dose verification for Liver Cancer Y-90 Radioembolization Personalized Dosimetry

(LSM P1) Factors Predicting Toxicity and Response Following Isolated Limb Infusion for Melanoma: An International Multi-center Analysis

(LSM P2) 40 Minutes is Enough: Lymphoscintigraphy with Novel Agent Reduces Time Needed for Mapping

(LSM P3) Active Surveillance of Melanoma Patients with Sentinel Node Metastasis: An International Multi-Institution Evaluation of post-MSLT-2 Adoption and Early Outcomes

(LSM P4) Adjuvant Therapy Failure Patterns in the Post-MSLT-2 era

(LSM P5) Exploring Head and Neck Melanoma Sentinel Lymph Node Outcome Compliance with Multicenter Selective Lymphadenectomy Trials Predicted Outcome

(LSM P6) Institutional Percutaneous Hepatic Perfusion (PHP) for Unresectable Liver Metastases

(LSM P7) The Physician Assistant's Role in Administering T-VEC for Advanced Melanoma: a Single Institution Experience